Phesgo or trastuzumab and pertuzumab

trastuzumab  If you're having trastuzumab to treat primary breast cancer after surgery, it's usually given for 1 year Some people may be offered trastuzumab beyond progression Trastuzumab is generally well tolerated and does not cause many of the toxicities or side effects seen with conventional

Trastuzumab emtansine binds to the HER2 receptor's sub-domain IV and goes into the cell by receptor-mediated endocytosis Lysosomes degrade trastuzumab Trastuzumab prolongs survival in metastatic breast cancer patients whose tumors over express HER2 It is effective when given as a single agent or in

Subcutaneous trastuzumab has a similar safety profile to intravenous trastuzumab and is non-inferior in terms of pharmacokinetic profile and efficacy and Trastuzumab ซึ่งสามารถลดอัตราการเสียชีวิตได้ถึง 24%และถ้าหากใช้ ยามุ่งเป้าชนิดต้าน HER2 – Trastuzumab กับ Pertuzumab ร่วมกับยาเคมีบำบัด จะสามารถลดอัตราการ